Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Video-interview with Prof. Pierre Fenaux about treatment with imetelstat provides durable transfusion
    independence in lower risk MDS patients relapsed/refractory to erythropoietic stimulating agents

2. Five-year follow-up data of RESONATE-2 underline the sustained clinical benefit of single-agent
    ibrutinib as frontline therapy for chronic lymphocytic leukemia

3. Subcutaneous daratumumab is non-inferior to the intravenous drug formulation in patients with
    relapsed or refractory multiple myeloma

4. Frontline brentuximab vedotin + AVD provides durable benefit over ABVD in patients with stage
    3/4 Hodgkin’s lymphoma

5. Single-agent gilteritinib improves response and survival in relapsed/refractory FLT3-mutated
    AML patients